Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.

Abstract

BACKGROUND:

Dual-targeted anti-HER2 therapy significantly improves outcomes in HER2-positive breast cancer and could be beneficial in other HER2-positive cancers. JACOB's end-of study analyses aimed to evaluate the long-term efficacy and safety of pertuzumab plus trastuzumab and chemotherapy for previously untreated HER2-positive metastatic gastric or gastroesophageal junction cancer.

METHODS:

Eligible patients were randomized 1:1 to pertuzumab/placebo plus trastuzumab and chemotherapy every 3 weeks.

PRIMARY ENDPOINT:

overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), and safety.

RESULTS:

The intention-to-treat population comprised 388 patients in the pertuzumab arm and 392 in the placebo arm. The safety population comprised 385 and 388 patients, respectively. Median follow-up was ≥ 44.4 months. Median OS was increased by 3.9 months (hazard ratio 0.85 [95% confidence intervals, 0.72-0.99]) and median PFS by 1.3 months (hazard ratio 0.73 [95% confidence intervals, 0.62-0.85]) in the pertuzumab vs. the placebo arm. ORR was numerically higher (57.0% vs. 48.6%) and median DoR 1.8 months longer with pertuzumab treatment. There was a trend for more favorable hazard ratios in certain subgroups related to HER2 amplification/overexpression. Safety was comparable between arms, except for serious and grade 3-5 adverse events, and any-grade diarrhea, which were more frequent with pertuzumab.

CONCLUSIONS:

JACOB did not meet its primary endpoint. Nonetheless, the study continues to demonstrate some, albeit limited, evidence of treatment activity and an acceptable safety profile for pertuzumab plus trastuzumab and chemotherapy in previously untreated HER2-positive metastatic gastric or gastroesophageal junction cancer after long-term follow-up. Trial registration NCT01774786; https://clinicaltrials.gov/ct2/show/NCT01774786 .

• Authors: Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Asna Siddiqui, Sarah Heeson, Astrid Kiermaier, Harrison Macharia, Eleonora Restuccia, Yoon-Koo Kang
• Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (Gastric Cancer) Vol. 26 Issue 1 Pg. 123-131 (01 2023) ISSN: 1436-3305 [Electronic] Japan
• PMID: 36066725 (Publication Type: Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article, Comment)
• Copyright: © 2022. The Author(s).

Chemical References

• Trastuzumab
• pertuzumab
• Receptor, ErbB-2
• Biomarkers, Tumor

Topics

• Humans
• Female
• Trastuzumab
• Receptor, ErbB-2
• Stomach Neoplasms (pathology)
• Biomarkers, Tumor
• Breast Neoplasms (pathology)
• Esophageal Neoplasms (pathology)
• Esophagogastric Junction (pathology)
• Antineoplastic Combined Chemotherapy Protocols